Cerus (CERS) Q4 2025 earnings review
Top-Line Momentum Masks Aggressive Margin Compression
Cerus capped off FY25 with record Q4 product revenue of $57.8M (+14% YoY), driven by a massive 36% surge in EMEA sales. The company successfully posted its second consecutive year of positive adjusted EBITDA ($9.5M). However, the top-line success contradicts a deteriorating profitability profile: product gross margins have steadily collapsed from 58.8% in Q1 to 51.5% in Q4. Management blames IFC therapeutic production costs, tariffs, and inflation. Looking ahead, FY26 guidance projects 9-11% product revenue growth—a deceleration from 2025's 14%—indicating that the easy growth from the initial IFC ramp may be stabilizing.
🐂 Bull Case
EMEA sales accelerated sharply, shifting from a 4% decline in Q1 to a 36% growth surge in Q4, fueled by the regional rollout of the new INT200 illuminator and core platelet franchise strength.
The company proved its business model can sustain profitability on an adjusted EBITDA basis ($9.5M in FY25 vs $5.7M in FY24) and generated $6.2M in operating cash flow in Q4.
🐻 Bear Case
Gross margins contracted 240 bps YoY in Q4 and 730 bps sequentially since Q1. Rising IFC therapeutic production costs and external macroeconomic headwinds are eroding the benefits of higher sales volume.
North American product revenue growth decelerated dramatically from 22% in Q1 to just 5% in Q4, signaling potential saturation or pricing pressure in the core U.S. platelet market.
⚖️ Verdict: ⚪
Neutral. Top-line execution and cash management are solid, but the severe and sustained compression of gross margins combined with a decelerating core North American market cap near-term upside.
Key Themes
Persistent Margin Squeeze Contradicts Operating Leverage Narrative
Despite management highlighting a 'strengthened financial foundation,' product gross margins have steadily declined all year: 58.8% (Q1) -> 55.2% (Q2) -> 53.4% (Q3) -> 51.5% (Q4). This compression is driven by higher production costs for the rapidly growing IFC segment, alongside trade regulations and inflation. If the shift to a kit-based IFC model does not quickly arrest this decline, incremental revenue will yield diminishing returns.
EMEA Accelerates While North America Decelerates
A severe regional divergence has emerged. North America, previously the growth engine, is decelerating sharply (falling from 22% growth in Q1 to 5% in Q4). Conversely, EMEA is accelerating dramatically, surging 36% in Q4 to $21.8M. The launch of the INT200 device in Europe and traction in the German market are clearly offsetting the U.S. slowdown.
IFC Adoption and Blood Centers of America Partnership
INTERCEPT Fibrinogen Complex (IFC) revenue grew 80% to $16.7M for the full year. Crucially, Cerus entered a group purchasing agreement in Q4 with Blood Centers of America, a cooperative managing ~50% of the U.S. blood supply. This provides the infrastructure needed to complete the transition from a direct-to-hospital model to a higher-volume kit model.
Macroeconomic & Tariff Headwinds
Management continues to cite ongoing trade regulation, import tariffs, and inflationary pressures as uncontrollable drags on gross margin. These macro factors are structurally elevating the cost of goods sold, directly impacting the bottom line.
Pipeline Innovation: INT200 and RBC Program
The next-generation INT200 LED illuminator is successfully driving European sales and is slated for a mid-2026 U.S. FDA PMA submission. Meanwhile, the German Red Cross INITIATE Phase 4 study acts as a vital commercial beachhead for Europe's largest market, bridging the gap until the critical European INTERCEPT Red Blood Cell CE Mark decision expected in H2 2026.
Rising R&D Expenses
R&D spending increased 15% for the full year to $67.7M, outpacing the 14% product revenue growth. This was driven by government contract activity, Red Blood Cell pipeline advancement, and U.S. INT200 development. Management must balance pipeline investment with the promise of sustained EBITDA profitability.
Other KPIs
Accelerating. Up 31% from $21.1M in FY24 (and +15% YoY in Q4). Driven largely by BARDA-related project advancement for the INTERCEPT Red Blood Cell system. This provides an excellent non-dilutive funding stream to support the elevated R&D spending.
Reversing the cash burn seen in the first half of the year (which was tied to inventory build). The company generated $8.1M in H2 2025, bringing the full-year total to $4.8M. Cash and short-term investments sit at a comfortable $82.9M.
Stable improvement. Narrowed from a net loss of $(20.9)M in FY24. The loss is largely driven by non-cash stock-based compensation and depreciation, allowing the company to print positive Adjusted EBITDA.
Guidance
Decelerating. Implies 9% to 11% YoY growth, a step down from the 14% growth achieved in FY25. This likely accounts for the maturing penetration in the North American platelet market and the transition of IFC to lower-priced kits.
Decelerating. Implies 20% to 30% YoY growth, compared to the ~80% growth generated in FY25. While volume (dose equivalents) is expected to grow robustly, the strategic shift to a kit-based blood center sales model lowers the recognized revenue per dose, muting top-line growth.
Key Questions
Gross Margin Floor
Product gross margins have compressed for four consecutive quarters down to 51.5%. How much of this is structural versus transitory, and where do you expect the margin floor to settle in FY26?
North America Deceleration
North American product revenue growth slowed to just 5% in Q4. Is this a function of market saturation, pricing pressures, or temporary inventory timing, and how does the new Blood Centers of America agreement impact this trajectory?
IFC Kit Model Economics
As IFC transitions almost entirely to a kit model by the end of 2026, when will the modeled improvements in gross margin begin to visibly offset the current therapeutic production cost headwinds?